Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8192756 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(3 months ago) | |
US8333992 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(3 months ago) | |
US8252332 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(3 months ago) | |
US7731989 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(3 months ago) | |
US7438927 | ALMATICA | Methods of treatment using a gastric retained gabapentin dosage |
Feb, 2024
(1 year, 25 days from now) |
Market Authorisation Date: 28 January, 2011
Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7256216 | VIATRIS | Liquid pharmaceutical compositions |
May, 2022
(8 months ago) | |
US7256216
(Pediatric) | VIATRIS | Liquid pharmaceutical compositions |
Nov, 2022
(2 months ago) |
Market Authorisation Date: 02 March, 2000
Treatment: NA
Dosage: SOLUTION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic